Hypermune Equine Plasma Products Availability
It is with great pleasure that we can confirm that the VMD have now agreed to remove the stop on the current stock of Hypermune and Hypermune-RE equine plasma products and these will be available as from week commencing 28th February 2022 for the current foaling season.
We welcome your feedback. To assist us in maintaining our uncompromising standards, please take a moment to tell us about clinical cases in which you used our products by completing this form: "How Are We Doing Clinically?".
If you wish to be on our email directory or make changes to your details please contact us.
HYPERMUNE RE has completed its first five years as an authorised veterinary medicinal product and in 2012 was granted a renewal "for life" by the Veterinary medicines Directorate and the Irish Medicines Board. The UK government Home Office has granted a new 5 year Project Licence for the company to continue producing plasma from horses until March 2022.
On 26th of May 2021 the UK regulatory authority, the Veterinary Medicines Directorate conducted its routine searching site inspection and processes at Veterinary Immunogenics Ltd. Once again the company proved it takes Good Manufacturing Practice very seriously by meeting all the high standards required and has been granted a new Good Manufacturing Practice certificate.
Following the sporadic incidents of Equine Infectious Anaemia in the United Kingdom in 2010 it is still reported by the authorities that the risk of spread or further incidents is considered to be very low. Nevertheless, Veterinary Immunogenics Ltd provides continuing assurance that HYPERMUNE and HYPERMUNE RE are produced in the United Kingdom in compliance with strict protocols to ensure consistent product quality and safety. These include the testing of every donor horse to ensure its freedom from a specified range of disease-causing agents including Equine Infectious Anaemia as well as constantly monitoring the UK horse health status for exotic and emerging diseases. Final product testing on every plasma harvest further endorses this standard.
HYPERMUNE and HYPERMUNE-RE have national UK Marketing Authorisations.
HYPERMUNE-RE has also been granted a full Marketing Authorisation by the Irish Medicines Board. This product is available for direct supply to Veterinary Surgeons in Ireland as well as the UK and carries harmonised labels and product literature.
The Veterinary Medicines Directorate has an updated list of licensed veterinary products online. For more online resources see the entries for Veterinary Immunogenics, HYPERMUNE and HYPERMUNE-RE in the UK National Office of Animal Health (NOAH) Compendium of Animal Medicines.
GAMMA CHECK KITS. Unfortunately we are unable to make these kits due to the world wide unavailability of one key component. Accurate testing for IgG is our recommendation using a laboratory based validated quantitative test.
We are very aware of the fluctuating exchange rates of currencies at the present time, particularly after the "Brexit" referendum result in the summer of 2016. We are therefore, striving to operate with maximum efficiency to restrain costs and thus strictly limit price increases only where absolutely necessary.
We attended Brexit meetings in Dublin and at the VMD headquarters in London but no valuable information has yet been learned regarding any changes that may impact the availability of HYPERMUNE and HYPERMUNE-RE after Brexit.
For more information on plasma use, in addition to Failure of Passive Transfer, see the HYPERMUNE-REview volume 1 (January 2009) and HYPERMUNE-REview volume 2 (January 2010). Please also see the Newsletters archives and FAQs avialable in the reference section of this site
For further information please contact us.
We continue our support of the industry through participation in particular events.